Construction of a Novel Clinical Stage-Related Gene Signature for Predicting Outcome and Immune Response in Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) with high heterogeneity is one of the most frequent malignant tumors. However, there were no studies to create a clinical stage-related gene signature for HCC patients. Differentially expressed genes (DEGs) associated with clinical stage of HCC were analyzed based on T...

Full description

Saved in:
Bibliographic Details
Main Authors: Liu Yang, Long-fei Zeng, Guo-qing Hong, Qing Luo, Xing Lai
Format: Article
Language:English
Published: Wiley 2022-01-01
Series:Journal of Immunology Research
Online Access:http://dx.doi.org/10.1155/2022/6535009
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849473482235052032
author Liu Yang
Long-fei Zeng
Guo-qing Hong
Qing Luo
Xing Lai
author_facet Liu Yang
Long-fei Zeng
Guo-qing Hong
Qing Luo
Xing Lai
author_sort Liu Yang
collection DOAJ
description Hepatocellular carcinoma (HCC) with high heterogeneity is one of the most frequent malignant tumors. However, there were no studies to create a clinical stage-related gene signature for HCC patients. Differentially expressed genes (DEGs) associated with clinical stage of HCC were analyzed based on TCGA datasets. Functional enrichment analysis was carried out by the use of stage-related DEGs. Then, the least absolute shrinkage and selection operator (LASSO) regression and univariate Cox regression were performed to reduce the overfit and the number of genes for further analysis. Next, survival and ROC assays were carried out to demonstrate the model using TCGA. Functional analysis and immune microenvironment analysis related to stage-related DEGs were performed. Reverse transcriptase polymerase chain reaction (RT-PCR) and Cell Counting Kit-8 (CCK-8) assays were applied to examine the expression and function of PNCK in HCC. In this research, there were 21 DEGs between HCC specimens with stage (I-II) and HCC specimens with stage (III-IV), including 20 increased genes and 1 decreased genes. A novel seven-gene signature (including PITX2, PNCK, GLIS1, SCNN1G, MMP1, ZNF488, and SHISA9) was created for the prediction of outcomes of HCC patients. The ROC curves confirmed the prognostic value of the new model. Cox assays demonstrated that the seven-gene signature can independently forecast overall survival. The immune analysis revealed that patients with low risk score exhibited more immune activities. Moreover, we confirmed that PNCK expressions were distinctly increased in HCC, and its silence suppressed the proliferation of HCC cells. Overall, our research offered a robust and reliable gene signature which displayed an important value in the prediction of overall survival of HCC patients and might deliver more effective personalized therapies.
format Article
id doaj-art-d2ec255793ca439c9ffbb6d1f513332e
institution Kabale University
issn 2314-7156
language English
publishDate 2022-01-01
publisher Wiley
record_format Article
series Journal of Immunology Research
spelling doaj-art-d2ec255793ca439c9ffbb6d1f513332e2025-08-20T03:24:07ZengWileyJournal of Immunology Research2314-71562022-01-01202210.1155/2022/6535009Construction of a Novel Clinical Stage-Related Gene Signature for Predicting Outcome and Immune Response in Hepatocellular CarcinomaLiu Yang0Long-fei Zeng1Guo-qing Hong2Qing Luo3Xing Lai4Department of HepatobiliaryDepartment of HepatobiliaryDepartment of Hepatobiliary SurgeryDepartment of Hepatobiliary SurgeryDepartment of Hepatobiliary SurgeryHepatocellular carcinoma (HCC) with high heterogeneity is one of the most frequent malignant tumors. However, there were no studies to create a clinical stage-related gene signature for HCC patients. Differentially expressed genes (DEGs) associated with clinical stage of HCC were analyzed based on TCGA datasets. Functional enrichment analysis was carried out by the use of stage-related DEGs. Then, the least absolute shrinkage and selection operator (LASSO) regression and univariate Cox regression were performed to reduce the overfit and the number of genes for further analysis. Next, survival and ROC assays were carried out to demonstrate the model using TCGA. Functional analysis and immune microenvironment analysis related to stage-related DEGs were performed. Reverse transcriptase polymerase chain reaction (RT-PCR) and Cell Counting Kit-8 (CCK-8) assays were applied to examine the expression and function of PNCK in HCC. In this research, there were 21 DEGs between HCC specimens with stage (I-II) and HCC specimens with stage (III-IV), including 20 increased genes and 1 decreased genes. A novel seven-gene signature (including PITX2, PNCK, GLIS1, SCNN1G, MMP1, ZNF488, and SHISA9) was created for the prediction of outcomes of HCC patients. The ROC curves confirmed the prognostic value of the new model. Cox assays demonstrated that the seven-gene signature can independently forecast overall survival. The immune analysis revealed that patients with low risk score exhibited more immune activities. Moreover, we confirmed that PNCK expressions were distinctly increased in HCC, and its silence suppressed the proliferation of HCC cells. Overall, our research offered a robust and reliable gene signature which displayed an important value in the prediction of overall survival of HCC patients and might deliver more effective personalized therapies.http://dx.doi.org/10.1155/2022/6535009
spellingShingle Liu Yang
Long-fei Zeng
Guo-qing Hong
Qing Luo
Xing Lai
Construction of a Novel Clinical Stage-Related Gene Signature for Predicting Outcome and Immune Response in Hepatocellular Carcinoma
Journal of Immunology Research
title Construction of a Novel Clinical Stage-Related Gene Signature for Predicting Outcome and Immune Response in Hepatocellular Carcinoma
title_full Construction of a Novel Clinical Stage-Related Gene Signature for Predicting Outcome and Immune Response in Hepatocellular Carcinoma
title_fullStr Construction of a Novel Clinical Stage-Related Gene Signature for Predicting Outcome and Immune Response in Hepatocellular Carcinoma
title_full_unstemmed Construction of a Novel Clinical Stage-Related Gene Signature for Predicting Outcome and Immune Response in Hepatocellular Carcinoma
title_short Construction of a Novel Clinical Stage-Related Gene Signature for Predicting Outcome and Immune Response in Hepatocellular Carcinoma
title_sort construction of a novel clinical stage related gene signature for predicting outcome and immune response in hepatocellular carcinoma
url http://dx.doi.org/10.1155/2022/6535009
work_keys_str_mv AT liuyang constructionofanovelclinicalstagerelatedgenesignatureforpredictingoutcomeandimmuneresponseinhepatocellularcarcinoma
AT longfeizeng constructionofanovelclinicalstagerelatedgenesignatureforpredictingoutcomeandimmuneresponseinhepatocellularcarcinoma
AT guoqinghong constructionofanovelclinicalstagerelatedgenesignatureforpredictingoutcomeandimmuneresponseinhepatocellularcarcinoma
AT qingluo constructionofanovelclinicalstagerelatedgenesignatureforpredictingoutcomeandimmuneresponseinhepatocellularcarcinoma
AT xinglai constructionofanovelclinicalstagerelatedgenesignatureforpredictingoutcomeandimmuneresponseinhepatocellularcarcinoma